Boston Scientific is pausing European sales of its next-generation Watchman FLX left-atrial appendage closure device after recording a higher rate of device embolization events compared to its first-generation system.
Boston Scientific initiated a limited market launch of the FLX system in November following a CE mark. The first-generation Watchman LAA closure device has been available in Europe since 2005...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?